Barclays Maintains Overweight on UnitedHealth Group, Raises Price Target to $465
Barclays analyst Steve Valiquette maintains UnitedHealth Group (NYSE:UNH) with a Overweight and raises the price target from $435 to $465.
Why Shares Of Biogen Are Trading Lower Today
Biogen (NASDAQ: BIIB) shares are trading lower after Cleveland Clinic said it would not administer the company's Aduhelm Alzheimer's medication, which has added to controversy surrounding the drug.
Morgan Stanley Records Impressive Quarter, Becoming Final Big Bank To Report
Big banks continue to hold up their end of the bargain, but the rest of the market doesn’t seem too impressed this morning. Major indices declined overnight amid worries about the Chinese economy, while slipping U.S. bond yields put a little pressure on things, too.
UnitedHealth Crushes Q2 Earnings, Lifts FY2021 Guidance
UnitedHealth Group Inc (NYSE: UNH) reports Q2 revenues of $71.3 billion, up 15% Y/Y and beating the consensus of $69.5 billion,…
UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate
UnitedHealth Group (NYSE:UNH) reported quarterly earnings of $4.70 per share which beat the analyst consensus estimate of $4.43 by 6.09 percent. This is a 33.99 percent decrease over earnings of $7.12 per share from the
Earnings Scheduled For July 15, 2021
Companies Reporting Before The Bell
• Truist Financial (NYSE:TFC) is estimated to report quarterly earnings at $1.17 per share on revenue of $5.47 billion.
Seaport Global Initiates Coverage On UnitedHealth Group with Buy Rating, Announces Price Target of $450
Seaport Global analyst Joseph France initiates coverage on UnitedHealth Group (NYSE:UNH) with a Buy rating and announces Price Target of $450.
UnitedHealthcare Highlights Use Of Predictive Analytics To Expand Its Capabilities To ‘Address Social Determinants Of Health’
New capability helps identify people in employer-sponsored benefit plans who are most likely in need of support, proactively connecting them to low- or no-cost community resources
Program builds on existing initiatives
Biogen’s Costly Alzheimer’s Treatment May Face Restricted Medicare Access: WSJ
The recent approval of Biogen Inc’s (NASDAQ:BIIB) high-price Alzheimer’s drug is raising questions about who will have access to the $56,000/year treatment…